Items where authors include "Gregory, W"

Article

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Gregory, W et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (11 more authors) (2022) Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, 107 (1). pp. 231-242. ISSN 0390-6078

Bird, S, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (12 more authors) (2021) Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clinical Lymphoma Myeloma and Leukemia, 21 (10). pp. 667-675. ISSN 2152-2650

Bygrave, C, Pawlyn, C, Davies, F et al. (11 more authors) (2021) Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma. British Journal of Haematology, 193 (3). pp. 551-555. ISSN 0007-1048

Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Kaiser, M et al. (11 more authors) (2020) The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, 34 (2). pp. 604-612. ISSN 0887-6924

Selby, P, Liu, L, Downing, A orcid.org/0000-0002-0335-7801 et al. (10 more authors) (2019) How can clinical research improve European health outcomes in cancer? Journal of Cancer Policy, 20. ARTN 100182. ISSN 2213-5383

Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2019) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology, 185 (3). pp. 573-578. ISSN 0007-1048

Coleman, RE, Collinson, M orcid.org/0000-0003-3568-6455, Gregory, W orcid.org/0000-0003-2641-8416 et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13. pp. 123-135. ISSN 2212-1374

Heaney, JLJ, Campbell, JP, Iqbal, G et al. (11 more authors) (2018) Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia, 32 (8). pp. 1727-1738. ISSN 0887-6924

Brown, J, Rathbone, E, Hinsley, S orcid.org/0000-0001-6903-4688 et al. (13 more authors) (2018) Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. Journal of the National Cancer Institute, 110 (8). pp. 871-879. ISSN 0027-8874

Gopalakrishna, G, Langendam, M, Scholten, R et al. (470 more authors) (2017) Erratum to: Methods for evaluating medical tests and biomarkers. Diagnostic and Prognostic Research, 1 (11). pp. 2-5.

Campbell, JP, Heaney, JLJ, Pandya, S et al. (10 more authors) (2017) Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematology. ISSN 2352-3026

Coleman, R, Hall, A, Albanell, J et al. (10 more authors) (2017) Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. The Lancet Oncology, 18 (11). pp. 1543-1552. ISSN 1470-2045

Campbell, JP, Heaney, JLJ, Pandya, S et al. (9 more authors) (2017) Active multiple myeloma suppresses and typically eliminates coexisting MGUS. British Journal of Cancer, 117 (6). pp. 835-839. ISSN 0007-0920

Brown, SR, Sherratt, D, Booth, G et al. (4 more authors) (2017) Experiences of Establishing an Academic Early Phase Clinical Trials Unit. Clinical Trials, 14 (4). pp. 349-356. ISSN 1740-7745

Gopalakrishna, G, Langendam, M, Scholten, R et al. (468 more authors) (2017) Erratum to: Methods for evaluating medical tests and biomarkers. Diagnostic and Prognostic Research, 1. 11. ISSN 2397-7523

Downing, A orcid.org/0000-0002-0335-7801, Morris, EJA orcid.org/0000-0002-1075-6544, Corrigan, N et al. (13 more authors) (2017) High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut, 66 (1). pp. 89-96. ISSN 0017-5749

Popat, R, Brown, SR, Flanagan, L et al. (9 more authors) (2016) Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet Haematology, 3 (12). e572-e580. ISSN 2352-3026

Hayes, J, Thygesen, H, Gregory, W et al. (5 more authors) (2016) A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Molecular Oncology, 10 (8). pp. 1296-1304. ISSN 1574-7891

Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688, Ballesteros, M et al. (11 more authors) (2016) The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC hematology, 16. p. 14. ISSN 2052-1839

Chaikin, L, Kashiwa, K, Bennet, M et al. (2 more authors) (2015) Microcurrent stimulation in the treatment of dry and wet macular degeneration. Clinical Ophthalmology, 9. pp. 2345-2353. ISSN 1177-5467

Schey, S, Brown, SR, Tillotson, A-L et al. (13 more authors) (2015) Bendamustine, thalidomide and dexamethasone combinationtherapy for relapsed/refractory myeloma patients: results ofthe MUKone randomized dose selection trial. British Journal of Haematology, 170 (3). pp. 336-348. ISSN 0007-1048

Coleman, RE, Gregory, W, Marshall, H et al. (2 more authors) (2013) The metastatic microenvironment of breast cancer: clinical implications. Breast, 22 S2. S50 - S56. ISSN 0960-9776

Hall, PS, Edlin, R, Kharroubi, S et al. (2 more authors) (2012) Expected net present value of sample information: from burden to investment. Medical Decision Making, 32 (3). E11 - E21. ISSN 0272-989X

Monograph

Selby, PJ, Banks, RE orcid.org/0000-0002-0042-8715, Gregory, W orcid.org/0000-0003-2641-8416 et al. (50 more authors) (2018) Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Report. NIHR Journals Library , Southampton, UK. ISSN 2050-4322

Conference or Workshop Item

Royle, K-L, Martin, A orcid.org/0000-0002-2559-6483, Meads, D et al. (2 more authors) (2019) P-103: Considerations for statistical analysis when QALYs are a co-primary endpoint in a large phase II/III randomised controlled trial. In: 5th International Clinical Trials Methodology Conference (ICTMC 2019), 06-09 Oct 2019, Brighton, UK.

Rawstron, A, Cohen, D, de Tute, R et al. (8 more authors) (2015) BONE MARROW IS MORE SENSITIVE THAN PERIPHERAL BLOOD FOR DETECTION OF MRD IN CLL AND PROVIDES A MORE RELIABLE PREDICTION OF OUTCOME ACROSS DIFFERENT TREATMENTS. In: European Haematology Association Congress, 11-14 Jun 2015, Vienna, Austria.

Proceedings Paper

Gopalakrishna, G, Langendam, M, Scholten, R et al. (468 more authors) (2017) Methods for Evaluating Medical Tests and Biomarkers. In: Diagnostic and Prognostic Research. Methods for evaluating medical tests and biomarkers: Symposium 2016, 19-20 Jul 2016, Birmingham, UK. BMC .

Bestall, JC orcid.org/0000-0001-6765-6379, Franks, KN, Collinson, F et al. (7 more authors) (2017) Exploring Recruitment Factors in a Feasibility Trial of SABR versus Surgery. In: Journal of Thoracic Oncology. IASLC 17th World Conference on Lung Cancer (IASLC WCLC 2016), 03-07 Dec 2016, Vienna. Elsevier , S1093-S1093.

Sebag-Montefiore, D, Adams, R, Bell, S et al. (17 more authors) (2016) The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus. In: Proceedings of the American Society for Radiation Oncology. 58th Annual Meeting of the American Society for Radiation Oncology, 25-28 Sep 2016. Elsevier , E164-E165.

Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2014) Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma. In: BLOOD. 56th ASH Annual Meeting 2014, 06-09 Dec 2014, San Francisco, California, USA. American Society of Hematology .